Key result
ICI therapy is linked to a ~32% incidence of new cardiovascular diagnoses in head and neck cancer.
Why the study?
Immune checkpoint inhibitors are a common treatment for head and neck cancer, but their immune-related cardiovascular adverse events can be clinically significant and require emergency department evaluation and treatment.
What is the frequency, timing, and emergency department utilization of cardiovascular events in recurrent or metastatic head and neck cancer patients treated with immune checkpoint inhibitors?
Cohort (n=610)
No
What is the frequency, timing, and emergency department utilization of cardiovascular events in recurrent or metastatic head and neck cancer patients treated with immune checkpoint inhibitors?
Nearly one-third of head and neck cancer patients without prior heart disease developed new cardiovascular diagnoses after starting immune checkpoint inhibitors, nearly half of which presented acutely to the emergency department, highlighting the need for cardio-oncology vigilance.
Answers are grounded in this paper and cite their sources.
May warrant closer cardiovascular surveillance in head and neck cancer immunotherapy; leaves open optimal screening and prevention strategies.
BACKGROUND: Cardio-oncology and emergency medicine are closely collaborative, as many cardiac events in cancer patients require evaluation and treatment in the emergency department (ED). Immune checkpoint inhibitors (ICIs) have become a common treatment for patients with head and neck cancer (HNC). However, the immune-related adverse events (irAEs) from ICIs can be clinically significant. METHODS: We reviewed and analyzed cardiovascular diagnoses among HNC patients who received ICI during the period April 1, 2016-December 31, 2020 in a large tertiary cancer center. Demographics, clinical and cancer-related data were abstracted, and billing databases were queried for cardiovascular disease (CVD)-related diagnosis using International Classification of Disease-version10 (ICD-10) codes. We recorded receipt of care at the ED as one of the outcome variables. RESULTS: A total of 610 HNC patients with a median follow-up time of 12.3 months (median, interquartile range = 5-30 months) comprised our study cohort. Overall, 25.7% of patients had pre-existing CVD prior to ICI treatment. Of the remaining 453 patients without pre-existing CVD, 31.5% (n = 143) had at least one CVD-related diagnosis after ICI initiation. Tachyarrhythmias (91 new events) was the most frequent CVD-related diagnosis after ICI. The time to diagnosis of myocarditis from initiation of ICI occurred the earliest (median 2.5 months, 1.5-6.8 months), followed by myocardial infarction (3.7, 0.5-9), cardiomyopathy (4.5, 1.6-7.3), and tachyarrhythmias (4.9, 1.2-11.4). Patients with myocarditis and tachyarrhythmias mainly presented to the ED for care. CONCLUSION: The use of ICI in HNC is still expanding and the spectrum of delayed manifestation of ICI-induced cardiovascular toxicities is yet to be fully defined in HNC survivors.
No takes yet. Share an insight, caveat, or question.
Reyes‐Gibby et al. (2023) conducted a cohort in Recurrent or metastatic head and neck cancer (R/M HNC) (n=610). Immune checkpoint inhibitors (predominantly pembrolizumab and nivolumab) was evaluated on Incident cardiovascular disease-related diagnosis after immune checkpoint inhibitor initiation among patients without pre-existing CVD (p=<0.05). Immune checkpoint inhibitor therapy in head and neck cancer patients without prior cardiovascular disease was associated with a 31.5% (n=143/453) incidence of new cardiovascular diagnoses.
Synapse has enriched 10 related papers. Consider them for comparative context: